Table 3: Summary of characteristics and features of the Abbott Libre, Dexcom G5 and Medtronic Enlite systems as indicated for use outside the US.

rtCGM

isCGM

Patients treated with intensive insulin regimens (insulin pump and MDI) Patients with increased risk for hypoglycaemia: Impaired hypoglycaemia awareness Frequent nocturnal hypoglycaemia Frequent severe hypoglycaemia Significant glycaemic variability Patients who experience hypoglycaemia fear Patients who are physically active (especially athletes) and/or have busy lifestyles Patients who cannot achieve adequate glucose control with isCGM Patients who desire tighter glucose control Younger T1D patients who require continuous support by an adult (parents, school personnel and coaches in sports via 'sharing', with specific alert settings) Patients who want to use LGS and/or PLGS functions to reduce hypoglycaemia

Patients with newly diagnosed T2D for episodic use as an educational tool T2D patients treated with noninsulintropic therapies for episodic use as an educational tool T2D patients who are not on intensive insulin regimens, are under good control and desire full-time or episodic isCGM as an alternative to SMBG Any T1D and T2D patients on insulin treatment who would like to monitor glucose without the support of alerts/alarms; and possibly transition to rtCGM in the future Patients who are motivated to scan their device several times per day, which is mandatory for improved glucose control (e.g., during pregnancy) Patients with low risk of hypoglycaemia but desire more data Patients who cannot afford rtCGM but desire improved glycaemic control or if a specific country specifies that isCGM is the first choice before rtCGM

isCGM = intermittently scanned continuous glucose monitoring; LGS = low glucose suspend function; MDI = multiple daily insulin injection; PLGS = predictive low glucose suspend function; rtCGM = real-time continuous glucose monitoring; SMBG = selfmonitoring of blood glucose; T1D = type 1 diabetes; T2D = type 2 diabetes.